Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
复制标题
DOI：
10.1371/journal.pone.0022854
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Parkinson Study Group DATATOP Investigators
中科院分区：
文献类型：
--
作者：
Huang X;Auinger P;Eberly S;Oakes D;Schwarzschild M;Ascherio A;Mailman R;Chen H;Parkinson Study Group DATATOP Investigators
最近的研究表明，较高的血清胆固醇可能与帕金森病（PD）的发生率较低有关。本研究旨在验证高血清胆固醇与PD进展较慢相关的假设。在1987年至1988年期间入组的800例早期PD受试者中，测量了774例基线非空腹血清总胆固醇，这些受试者参加了丙炔苯丙胺和生育酚抗氧化治疗帕金森症（DATATOP）试验。参与者被随访长达两年，需要左旋多巴治疗的临床残疾作为主要终点。在调整混杂因素后，确定了需要左旋多巴治疗的临床残疾患者血清胆固醇浓度升高的风险比（HR）和95%置信区间（CI）。基线时，仅9例受试者报告使用降胆固醇药物（2例使用他汀类药物）。总体平均胆固醇水平为216 mg/dL（范围100 - 355）。进展至主要终点的HR随血清胆固醇浓度升高而降低。与最低五分位数相比，每个较高五分位数（按升序排列）的HR（95%CI）分别为0.83（0.59 - 1.16）、0.86（0.61 - 1.20）、0.84（0.60 - 1.18）和0.75（0.52 - 1.09）。一个标准差（SD）增加的HR = 0.90 [（0.80 - 1.01），趋势p = 0.09]。 在雄性动物中观察到该趋势（HR/SD = 0.88 [（0.77 - 1.00），趋势p = 0.05]，但在雌性动物中未观察到[HR = 1.03（0.81 - 1.32）]。 DATATOP试验的二次分析提供了初步证据，即较高的血清总胆固醇浓度可能与PD的临床进展适度较慢相关，这一初步发现需要更大规模的前瞻性研究证实。
Recent studies have suggested that higher serum cholesterol may be associated with lower occurrence of Parkinson's disease (PD). This study is to test the hypothesis that higher serum cholesterol correlates with slower PD progression. Baseline non-fasting serum total cholesterol was measured in 774 of the 800 subjects with early PD enrolled between 1987 and 1988 in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. Participants were followed for up to two years, with clinical disability requiring levodopa therapy as the primary endpoint. Hazard ratios (HRs) and 95% confidence intervals (CI) were determined for increasing serum cholesterol concentration (in quintiles) for clinical disability requiring levodopa therapy, after adjusting for confounders. At baseline, only nine subjects reported use of cholesterol-lowering agents (two with statins). The overall mean cholesterol level was 216 mg/dL (range 100–355). The HR of progressing to the primary endpoint decreased with increasing serum cholesterol concentrations. Compared to the lowest quintile, the HRs (95%CI), for each higher quintile (in ascending order) are 0.83 (0.59–1.16); 0.86 (0.61–1.20); 0.84 (0.60–1.18); and 0.75 (0.52–1.09). The HR for one standard deviation (SD) increase = 0.90 [(0.80–1.01), p for trend = 0.09]. This trend was found in males (HR per SD = 0.88 [(0.77–1.00), p for trend = 0.05], but not in females [HR = 1.03 (0.81–1.32)]. This secondary analysis of the DATATOP trial provides preliminary evidence that higher total serum cholesterol concentrations may be associated with a modest slower clinical progression of PD, and this preliminary finding needs confirmation from larger prospective studies.
登录
查看更多内容
影响因子：
4.8
作者：
Hashimoto, M;Bar-on, P;Masliah, E
通讯作者：
Masliah, E
影响因子：
9.9
作者：
JANKOVIC, J;MCDERMOTT, M;WEINER, W
通讯作者：
WEINER, W
影响因子：
--
作者：
Schwarzschild, Michael A.;Schwid, Steven R.;Ascherio, Alberto
通讯作者：
Ascherio, Alberto
影响因子：
4.4
作者：
Miyake, Yoshihiro;Tanaka, Keiko;Nagai, Masaki
通讯作者：
Nagai, Masaki
影响因子：
3.4
作者：
Rougé-Pont, F;Mayo, W;Piazza, PV
通讯作者：
Piazza, PV